Myoma Uteri

myomauteri-1-0-25kapak

Epidemiology of Leiomyomas

Mohammad İbrahim Halilzade

Ankara Bilkent City Hospital, Department of Gynecology and Obstetrics, Ankara, Türkiye

Halilzade Mİ. Epidemiology of Leiomyomas. Yavuz AF, ed. Myoma Uteri. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.13-19.

ABSTRACT

Uterine leiomyomas, commonly known as fibroids, are the most prevalent benign tumors of the fe- male pelvis. Uterine leiomyomas are highly common, with estimates suggesting that up to 70-80% of women will develop them by the age of 50 years. The prevalence of these tumors varies according to age, ethnicity, and other demographic factors. Understanding their prevalence, risk factors, and demo- graphic variation is essential for developing targeted interventions and improving patient outcomes. This article provides an overview of the epidemiological aspects of uterine leiomyomas, including their prevalence, risk factors, and demographic variation.

Keywords: Leiomyoma; Epidemiology; Risk factors

Referanslar

  1. Bozini N, Baracat EC. The history of myomectomy at the Medical School of University of São Paulo. Clinics (Sao Paulo). 2007;62(3):209-10. [Crossref]  [PubMed]
  2. Borahay MA, Al-Hendy A, Kilic GS, Boehning D. Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy. Mol Med. 2015;21(1):242-56. [Crossref]  [PubMed]  [PMC]
  3. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501-1512. [Crossref]  [PubMed]
  4. Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. Nat Rev Dis Primers. 2016;2:16043. [Crossref]  [PubMed]
  5. Wise LA, Laughlin-Tommaso SK. Epidemiology of Uterine Fibroids: From Menarche to Menopause. Clin Obstet Gynecol. 2016;59(1):2-24. [Crossref]  [PubMed]  [PMC]
  6. Wise LA, Palmer JR, Stewart EA, Rosenberg L. Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study. Obstet Gynecol. 2005;105(3):563-8. [Crossref]  [PubMed]  [PMC]
  7. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90(6):967-73. [Crossref]  [PubMed]
  8. Huang D, Magaoay B, Rosen MP, Cedars MI. Presence of Fibroids on Transvaginal Ultrasonography in a Community-Based, Diverse Cohort of 996 Reproductive-Age Female Participants. JAMA Netw Open. 2023;6(5):e2312701. [Crossref]  [PubMed]  [PMC]
  9. Ciarmela P, Ciavattini A, Giannubilo SR, Lamanna P, Fiorini R, Tranquilli AL, et al. Management of leiomyomas in perimenopausal women. Maturitas. 2014;78(3):168-73. [Crossref]  [PubMed]
  10. Wegienka G, Havstad S, Coleman C, Cooper T, Wesselink A, Upson K, et al. Ultrasound-Confirmed, Age-Specific Uterine Leiomyoma Incidence in a Cohort of Black Individuals. Obstet Gynecol. 2022;140(6):1042-1048. [Crossref]  [PubMed]  [PMC]
  11. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-7. [Crossref]  [PubMed]
  12. Downes E, Sikirica V, Gilabert-Estelles J, Bolge SC, Dodd SL, Maroulis C, et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):96-102. [Crossref]  [PubMed]
  13. Aksu F, Gezer A, Oral E. Seventeen-year review of hysterectomy procedures in a university clinic in Istanbul (1985- 2001). Arch Gynecol Obstet. 2004;270(4):217-22. [Crossref]  [PubMed]
  14. Mathew RP, Francis S, Jayaram V, Anvarsadath S. Uterine leiomyomas revisited with review of literature. Abdom Radiol (NY). 2021;46(10):4908-4926. [Crossref]  [PubMed]
  15. Han SC, Kim MD, Jung DC, Lee M, Lee MS, Park SI, et al. Degeneration of leiomyoma in patients referred for uterine fibroid embolization: incidence, imaging features and clinical characteristics. Yonsei Med J. 2013;54(1):215-9. [Crossref]  [PubMed]  [PMC]
  16. Sun S, Bonaffini PA, Nougaret S, Fournier L, Dohan A, Chong J, et al. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging. 2019;100(10):619-634. [Crossref]  [PubMed]
  17. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994;83(3):414-8. [PubMed]
  18. Taşdemir Ü, Ceran MU, Önder Dirican A, Akar S, Çelik Ç, Energin H, et al. Incidence of unexpected leiomyosarcoma in a Turkish province: a retrospective multi-centre study in a low income setting. J Obstet Gynaecol. 2022;42(6):2208-2212. [Crossref]  [PubMed]
  19. Reis FM, Bloise E, Ortiga-Carvalho TM. Hormones and pathogenesis of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016;34:13-24. [Crossref]  [PubMed]
  20. Moravek MB, Yin P, Ono M, Coon JS 5th, Dyson MT, Navarro A, et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update. 2015;21(1):1-12. [Crossref]  [PubMed]  [PMC]
  21. Dragomir AD, Schroeder JC, Connolly A, Kupper LL, Hill MC, Olshan AF, et al. Potential risk factors associated with subtypes of uterine leiomyomata. Reprod Sci. 2010;17(11):1029-35. [Crossref]  [PubMed]
  22. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004;159(2):113-23. [Crossref]  [PubMed]  [PMC]
  23. Terry KL, De Vivo I, Hankinson SE, Missmer SA. Reproductive characteristics and risk of uterine leiomyomata. Fertil Steril. 2010;94(7):2703-7. [Crossref]  [PubMed]  [PMC]
  24. Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology. 2003;14(2):247-50. [Crossref]  [PubMed]
  25. Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol.1999;106(8):857-60. [Crossref]  [PubMed]
  26. Harmon QE, Patchel SA, Zhao S, Umbach DM, Cooper TE, Baird DD. Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma. Obstet Gynecol. 2022;139(5):797-807. [Crossref]  [PubMed]  [PMC]
  27. Gunes M, Ozdegirmenci O, Kayikcioglu F, Haberal A, Kaplan M. The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study. J Minim Invasive Gynecol. 2008;15(6):735-8. [Crossref]  [PubMed]
  28. Baird DD, Newbold R. Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development. Reprod Toxicol. 2005;20(1):81-4. [Crossref]  [PubMed]
  29. James-Todd TM, Chiu YH, Zota AR. Racial/ethnic disparities in environmental endocrine disrupting chemicals and women's reproductive health outcomes: epidemiological examples across the life course. Curr Epidemiol Rep. 2016;3(2):161-180. [Crossref]  [PubMed]  [PMC]
  30. Terry KL, De Vivo I, Hankinson SE, Spiegelman D, Wise LA, Missmer SA. Anthropometric characteristics and risk of uterine leiomyoma. Epidemiology. 2007;18(6):758-763. [Crossref]  [PubMed]
  31. Wise LA, Palmer JR, Spiegelman D, Harlow BL, Stewart EA, Adams-Campbell LL, et al. Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S. black women. Epidemiology. 2005;16(3):346-354. [Crossref]  [PubMed]  [PMC]
  32. Wise LA, Radin RG, Palmer JR, Kumanyika SK, Boggs DA, Rosenberg L. Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata. Am J Clin Nutr. 2011;94(6):1620-1631. [Crossref]  [PubMed]  [PMC]
  33. Radin RG, Palmer JR, Rosenberg L, Kumanyika SK, Wise LA. Dietary glycemic index and load in relation to risk of uterine leiomyomata in the Black Women's Health Study. Am J Clin Nutr. 2010;91(5):1281-1288. [Crossref]  [PubMed]  [PMC]
  34. Brasky TM, Bethea TN, Wesselink AK, Wegienka GR, Baird DD, Wise LA. Dietary Fat Intake and Risk of Uterine Leiomyomata: A Prospective Ultrasound Study. Am J Epidemiol. 2020;189(12):1538-1546. [Crossref]  [PubMed]  [PMC]
  35. Terry KL, Missmer SA, Hankinson SE, Willett WC, De Vivo I. Lycopene and other carotenoid intake in relation to risk of uterine leiomyomata. Am J Obstet Gynecol. 2008;198(1):37.e1-37.e378. [Crossref]  [PubMed]  [PMC]
  36. Wise LA, Radin RG, Palmer JR, Kumanyika SK, Rosenberg L. A prospective study of dairy intake and risk of uterine leiomyomata. Am J Epidemiol. 2010;171(2):221-232. [Crossref]  [PubMed]  [PMC]
  37. Zhao G, Ford ES, Tsai J, Li C, Croft JB. Factors Associated with Vitamin D Deficiency and Inadequacy among Women of Childbearing Age in the United States. ISRN Obstet Gynecol. 2012;2012:691486. [Crossref]  [PubMed]  [PMC]
  38. Halder SK, Sharan C, Al-Hendy A. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012;86(4):116. [Crossref]  [PubMed]  [PMC]
  39. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study. Hum Reprod. 2004;19(8):1746-1754. [Crossref]  [PubMed]  [PMC]
  40. Wesselink AK, Wegienka G, Coleman CM, Geller RJ, Harmon QE, Upson K, et al. A prospective ultrasound study of cigarette smoking and uterine leiomyomata incidence and growth. Am J Obstet Gynecol. 2023;229(2):151.e1-151.e8. [Crossref]  [PubMed]  [PMC]
  41. Mäkinen N, Vahteristo P, Bützow R, Sjöberg J, Aaltonen LA. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas. Int J Cancer. 2014;134(4):1008-1012. [Crossref]  [PubMed]
  42. Langton CR, Harmon QE, Baird DD. Family History and Uterine Fibroid Development in Black and African American Women. JAMA Netw Open. 2024;7(4):e244185. [Crossref]  [PubMed]  [PMC]
  43. Harmon QE, Actkins KV, Baird DD. Fibroid Prevalence-Still So Much to Learn. JAMA Netw Open. 2023;6(5):e2312682. [Crossref]  [PubMed]
  44. Ishikawa H, Reierstad S, Demura M, Rademaker AW, Kasai T, Inoue M, et al. High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab. 2009;94(5):1752-1756. [Crossref]  [PubMed]  [PMC]
  45. Qin H, Lin Z, Vásquez E, Xu L. The association between chronic psychological stress and uterine fibroids risk: A meta-analysis of observational studies. Stress Health. 2019;35(5):585-594. [Crossref]  [PubMed]
  46. Vines AI, Ta M, Esserman DA. The association between self-reported major life events and the presence of uterine fibroids. Womens Health Issues. 2010;20(4):294-298. [Crossref]  [PubMed]  [PMC]
  47. Fischer NM, Nieuwenhuis TO, Singh B, Yenokyan G, Segars JH. Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women. J Clin Endocrinol Metab. 2021;106(2):e650-e659. [Crossref]  [PubMed]  [PMC]
  48. Velez Edwards DR, Hartmann KE, Wellons M, Shah A, Xu H, Edwards TL. Evaluating the role of race and medication in protection of uterine fibroids by type 2 diabetes exposure. BMC Womens Health. 2017;17(1):28. [Crossref]  [PubMed]  [PMC]
  49. Moore KR, Cole SR, Dittmer DP, Schoenbach VJ, Smith JS, Baird DD. Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids in African-American Women. J Womens Health (Larchmt).2015;24(6):489-495. [Crossref]  [PubMed]  [PMC]
  50. Moore KR, Smith JS, Cole SR, Dittmer DP, Schoenbach VJ, Baird DD. Chlamydia trachomatis Seroprevalence and Ultrasound-Diagnosed Uterine Fibroids in a Large Population of Young African-American Women. Am J Epidemiol. 2018;187(2):278-286. [Crossref]  [PubMed]  [PMC]